FDA: Dapagliflozin is effective for diabetes but has safety issues

07/17/2011 | Bloomberg · Reuters

FDA staff members gave a mixed review of AstraZeneca and Bristol-Myers Squibb's dapagliflozin, saying the drug candidate works against diabetes but poses serious risks. Trial data showed a higher incidence of breast and bladder cancer in dapagliflozin users, and the medicine appeared less effective in those with impaired kidney function, the agency said. An advisory panel is scheduled Tuesday to review the drug.

View Full Article in:

Bloomberg · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ